RU1779374C - Method for treating vertebrogenic pain syndrome - Google Patents

Abstract

The invention relates to medicine, namely to neurology. The method improves the therapeutic efficacy of the treatment. For this, drug therapy is supplemented by intramuscular administration of emoxipin.

Description

The invention relates to medicine, in particular to neurology, and can be used to treat vertebral pain.

To relieve vertebrogenic pain syndrome, the following actions are used:

anti-edematous and anti-inflammatory;

- resolving;

-improving microcirculation;

-Temporarily shutting off pain impulses;

-increasing the tolerance of nerve tissue and hypoxia,

The following methods of treating vertebrogenic pain syndrome are known: traction, manual therapy, massage, oral administration of non-narcotic analgesics, decongestants, antihistamines, tranquilizers. Paravertebral and epidural drug blockages, diadynamic and sinusoidally modulated currents, ultrasound, applications of the drug mixture of dimexide and novocaine, rubbing the skin with ointments containing snake or bee d, can or acupressure have similar effects.

In medical practice, the local use of enzymes with a resolving effect: lidase, trypsin, chymotrypsin (in the composition of the drug mixture for blockade, in electrophoresis) has proven itself well. But this method has a number of disadvantages:

-requires a sufficient knowledge of the blockade technique by a neurologist;

- unable to affect tissue regeneration;

- due to possible complications, it is practically not used in outpatient practice;

- there is no effect on vascular and gemic factors;

-does not have the actual anti-inflammatory effect;

- unable to increase the tolerance of nervous tissue to hypoxia.

Until recently, the use of agents that improve metabolism: vitamins, especially group B, adenosine triphosphoric acid, riboxin, was exacerbated when exacerbating diseases of the peripheral nervous system. But their use also has a number of disadvantages:

-Do not improve the rheological properties of blood;

with C

vj vi about to

vj Jb.

-the effect of these drugs on pain itself is ineffective;

-practically do not have a resolving effect;

- there is no impact on the microvasculature.

In addition, in order to improve microcirculation, to combat local ischemia and acidosis, vasoactive drugs of various groups are widely used: peripheral vasodialators. venotonic drugs, ganglion blockers in small doses.

The disadvantages of their use:

their effect in monotherapy is low, a long (up to 2 months) course of treatment is required;

- do not have a scattering effect:

- unable to increase the latent period of pathological reactions associated with ischemia;

-Do not reduce the need for brain tissue in oxygen.

For the treatment of sciatica and neuralgia, biogenic stimulants such as aloe extract, FIBS, peloid distillate, humisol, suspension of the placenta for injection, vitreous body, plasmol, rumanon (Mashkovsky M.D., Karpov V.A.) are widely used. ) Features of the action of biogenic stimulants are: enhanced metabolic and regenerative processes, general tonic and, in some cases, anti-inflammatory effects (plasmol, vitreous body), as well as absorbable. Among the disadvantages of the pharmacological action of the prototype should be noted:

-the need for parallel administration of vasoactive drugs that improve local blood flow,

- there is no protective effect on the tolerance of ischemia by the nervous tissue;

- Does not reduce the oxygen demand of the nerve tissue.

The aim of the invention is to increase the effectiveness and feasibility of a differentiated approach to the treatment of patients with neurological manifestations of lumbar osteochondrosis.

The goal is achieved in that, along with the traditional treatment of this pathology, patients are daily injected with 1 ml of 1% solution of the new domestic preparation Emoxipin (emoxipin-2-ethide b-methyl-3-hydroxypyridine hydrochloride) for 10 days.

In contrast to the prototype for the relief of pain caused by a significant

at least local ischemia, the drug Emoxipin is prescribed, which indicates the compliance of the claimed solution with the criterion of Novelty.

Symptom - the use of emoxipin

for the treatment of vertebrogenic pain syndrome - has never been used before for the proposed purpose, therefore, the claimed solution meets the criterion

0 Significant differences.

The use of exchange-rate treatment with vertebrogenic pain with emoxipin provides a new positive effect; a faster and more stable decrease in the intensity of pain, a decrease in the patient's stay in the clinic by 5.3 days, and a decrease in the total cost of treatment. One can also assume a longer remission.

0 Especially shown is the use of emoxipin in combined cerebral-vertebrogenic, vertebrogenic-somatic pathology, in the presence of vascular and adhesive components in the pathogenesis of neurological manifestations of lumbar osteochondrosis. Example. Kolesov LB, 35 years old, medical history N 11988, was admitted to the clinic of nervous diseases of the Military Medical Academy 10.09.90 with complaints of constant,

0 dramatically aggravated by any movement, coughing, sneezing, pain in the lumbar and right thighs, spreading along the lateral surface of the leg to the outer ankle, numbness in the zone of distribution

5 pains. Prior to admission to the clinic for 2 months, he was treated on an outpatient basis - without effect. Neurological status: pronounced antalgic tension of the long muscles of the back, flattening along the lumbar laryngeal dose, half-bent leg homolaterally, lack of a knee reflex on the right, decreased strength of the quadriceps femoris, extensors of the foot and thumb on the right. Functional block of movements in

5 along the lumbar spine, hypesthesia in PA dermatomes - LB on the right, severe symptoms of tension.

Diagnosis: exacerbation of vertebrogenic Lz - Le radiculitis on the right with pain syndrome. Piriformis syndrome on the right. The consequences of traumatic brain injury with asthenic syndrome. Against the background of treatment received at the clinic, which included rest, analgesics, diuretics, ultrasound, massage 5, novocaine blockade, the patient received a course of emoxipin - 10 injections.

The pain syndrome stopped, the patient was discharged after recovery after 17 days, and only discharge on lumbar lordosis remained upon discharge.

The claimed method allows to reliably relieve pain vertebrogenic syndrome by 1-2 weeks, reduce the patient’s stay in the clinic by 5.3 kodes, is aimed at preventing the development of complications (aseptic reactive spinal arachnoiditis and epiduritis, the development of focal lesions of the nervous system), It creates favorable conditions for the development of sanogenetic regenerative processes in the tissues of the spine, quickly and effectively affects the foci of neuro-myosteofibrosis, and is economically viable. There were no complications, allergic reactions. The method is technically simple, does not require any additional conditions and equipment, and can be quickly introduced into the practice of hospitals and clinics.

The pain syndrome in neurological manifestations is caused by the irritation of ischemic spinal nerves under mechanical influence of edematous neighboring tissues, adhesions under conditions of developing persistent tissue acidosis against the background of a decrease in microcirculation, a decrease in local metabolism, and ischemia. Therefore, the following directions of action are used to relieve the sick syndrome: decongestant and anti-inflammatory, resolving, improving microcirculation, temporarily disabling pain impulses, increasing the tolerance of nerve tissue and hypoxia, stimulating the regeneration of the intervertebral disc.

The main pharmacological properties of emoxipin are a decrease in vascular wall permeability, a decrease in blood viscosity and platelet aggregation, and an increase in the level of cyclic nucleotides in tissue thrombocytes (Mashkovsky M. D.). The high absorbable activity of emoxipin in ophthalmic practice has previously been proven. According to the literature (Leskova N.N., Chekneva N.S., Strakhovska L.V. In the collection Actual problems of neurology. Frunze, 1989, pp. 114-116. Pashin E.G., Shvedova A.A. Vli the synthesis of the synthetic antioxidant Emoxipin on the tone of the coronary vessels // Pharmacologists and Toxicologists. 1989, v. 52, p. 17-18) emoxipin improves cerebral blood flow, increases the latent period of pathological manifestations associated with ischemia, prevents the development of focal neurological symptoms , and also reduces the risk of developing hemorrhages, reduces the need for nervous tissue for Ki lorode.

Claims (1)

The indicated pharmacological properties of emoxipin can achieve a therapeutic effect in painful cases of neurological manifestations of lumbar osteochondrosis when used in complex treatment with fewer medications required to achieve a pain-free state and to prevent the development of relapses and complications associated with adhesion formation. SUMMARY OF THE INVENTION A method of treating a helicobogenous pain syndrome by administering drugs, characterized in that, in order to increase the therapeutic effectiveness of the treatment, emoxipin is additionally administered.